ALAMEDA, Calif.--(BUSINESS WIRE)--AllCells, LLC, (the “company”) has long been recognized as a leading industry provider of hematologic tissue, primary cell products (healthy & diseased), and cell-based assay services (“Bioservices”) which support global life science research. The company today announced its expansion into therapeutic applications through the introduction of clinical grade products for further processing of allogeneic cell therapies. AllCells will initially introduce standard (and custom) pack sizes of Clinical Grade Fresh Whole Bone Marrow early 2016, followed by Clinical Grade Fresh Leuko Pak products.
These clinical grade products serve as a rich source of adult human stem cells such as CD34+ hematopoietic stem and progenitor cells (HSPCs) capable of differentiating into various mature blood cell types, and/or mesenchymal stem cells (found in bone marrow) which are capable of differentiating into different tissues such as cartilage, bone, or fat. The company’s President & CEO, Jay Tong, M.D had this to say about the company’s plan to introduce clinical grade products:
“AllCells’ commitment and vision is to continue utilizing its strengths in hematology and immunology in ways that can make a greater impact on improving patient health, especially within the area of regenerative medicine. By providing a consistently high quality, readily available commercial source of HSC-rich products that comply with US-FDA cellular & tissue therapy regulations, we will help customers accelerate their manufacturing scale-up efforts and development timelines. Moreover, we specialize in handling customized hematologic tissue procurement made possible through LeukoLab – a clinical division of AllCells, in cases where our customers have distinct tissue collection criteria deemed critical for bioprocess requirements and/or product efficacy.”
During the past several months, the company has been enhancing its quality system to comply with US-FDA 21 CFR regulations. Additionally, AllCells maintains Biologics and Tissue Bank licenses from the California Dept. of Public Health. LeukoLab, a clinical division of AllCells, holds a clinical laboratory license. Human tissue collection protocols are approved by the company’s Medical Director and Independent Review Board (IRB) in accordance with federal law.
AllCells maintains a sizeable database of human donors, and this repository is constantly increasing. For more information about the availability of clinical grade products, contact us at P 1-888 535 3444, P 1-501-521-2600, and firstname.lastname@example.org.
About AllCells, LLC
AllCells (www.allcells.com) is a biotechnology company founded in 1998 to provide global researchers and biomanufacturing organizations with a reliable supply of biologically relevant, high quality primary cells (healthy & diseased) which enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease, stem cell research, and development of tissue, cell, and gene therapies. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes, hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for applications in which in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce the time needed to isolate cells with guaranteed consistency, thereby improving the efficiency, accuracy and relevance of their research studies or therapeutic development projects. AllCells is fully certified in accordance with local, state and federal requirements.